针对激素难治性前列腺癌患者主导症状病灶的姑息性放疗(PRADO)
这是一项国际多中心单臂前瞻性可行性研究,计划纳入34例伴主导性衰弱症状的激素难治性前列腺癌患者,对主导症状病灶行4次5 Gy高精度放疗、对病灶最侵袭部分行4次7 Gy同步整合推量,主要终点为可行性(完成放疗且接受≥90%处方剂量的患者比例)。
要点
- 研究计划纳入34例激素难治性前列腺癌伴主导性衰弱症状患者。
- 主导症状病灶接受4次5 Gy,病灶最侵袭部分接受4次7 Gy同步整合推量。
- 主要终点为可行性,即完成放疗且接受≥90%处方剂量的患者比例。
核心结论
- 若该新放疗方案被证明可行,将设计前瞻性随机II/III期剂量递增研究以改善症状性转移性激素难治性前列腺癌姑息性放疗的结局。
- 研究正在进行中,即将开始招募患者。
研究设计与样本
- 国际多中心单臂前瞻性可行性研究,计划纳入34例激素难治性前列腺癌伴主导性衰弱症状的患者。
- 主导症状病灶(GTV1)依据T2加权MRI和CT手动勾画,病灶最侵袭部分(GTV2)依据表观扩散系数(ADC)图定义。
- 辅助体积仅包括GTV1中ADC值低于1200×10-6 mm2/s的体素,最侵袭部分定义为ADC值低于中位ADC值的体素。
主要发现
- 主要终点为可行性,即完成放疗且接受≥90%处方剂量的患者比例。
- 次要终点包括主导症状评分、无进展生存(无症状生存)、总生存、急性毒性、生活质量、ADC从基线至治疗结束及治疗后6个月的变化。
关键数值与推荐
- 主导症状病灶接受4次5 Gy高精度放疗。
- 病灶最侵袭部分接受4次7 Gy同步整合推量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study was conducted to investigate a new short-course radiotherapy regimen for patients with metastatic hormone refractory prostate cancer (HRPC) presenting with a dominant debilitating symptom. METHODS / DESIGN: This is an international, multi-center single arm prospective feasibility study that aims to include 34 patients with HRPC and a dominant debilitating symptom. The dominant symptomatic lesion will receive 4 × 5 Gy of high-precision radiotherapy, and the most aggressive part of the lesion 4 × 7 Gy using a simultaneous integrated boost technique. Based on advanced magnetic resonance imaging (MRI), an apparent diffusion coefficient (ADC) map will be calculated for the lesion using diffusion weighted imaging sequences. The dominant symptomatic lesion (GTV1) is drawn manually using the information from T2w-MRI and computed tomography scans. The most aggressive part of the dominant lesion (GTV2) is defined by using the ADC map. An auxiliary volume is created including only voxels in the GTV1 that presents with ADC values below 1200 × 10- 6 mm2/s. The most aggressive part is defined as voxels with an ADC value below the median ADC value. Primary endpoint is feasibility, i.e. proportion of patients who complete radiotherapy with ≥90% of the prescribed dose. Secondary endpoints include dominant symptom score, progression-free survival (freedom from symptoms), overall survival, acute toxicity, quality of life, change in ADC from baseline to end of treatment and 6 months following treatment. DISCUSSION: If this new radiotherapy regimen proves to be feasible, a prospective randomized phase II/III dose escalation study will be designed in order to improve the outcomes of palliative radiotherapy of symptomatic metastatic HRPC. STUDY STATUS: The study is ongoing and will be recruiting patients soon. TRIAL REGISTRATION: clinicaltrials.gov NCT03658434 . Initially registered on 30th of July, 2018.
引用
- Carl J, Rades D, Doemer C, et al. Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO). Radiat Oncol. 2019. PMID: 30630502. doi:10.1186/s13014-019-1209-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。